

Emergent BioSolutions Company Overview

*Singular Research -- Spring Select 2023
Webinar*

Robert Burrows
VP, IRO

May 24, 2023

EMERGENT[®]



INTRODUCTION

Safe Harbor Statement/Trademarks

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or our business strategy, future operations, future financial position, future revenues and earnings, projected costs, prospects, plans and objectives of management and the ongoing impact of the COVID-19 pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasures, including AV7909 (Anthrax Vaccine Adsorbed (AVA), Adjuvanted), BioThrax® (Anthrax Vaccine Adsorbed) and ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live), among others, as well as contracts related to development of medical countermeasures; our ability to meet our commitments to quality and compliance in all of our manufacturing operations; our ability to negotiate additional USG procurement or follow-on contracts for our medical countermeasures products that have expired or will be expiring; the commercial availability, including the timing of availability, of over-the-counter NARCAN® (naloxone HCl) Nasal Spray; the impact of the generic marketplace on NARCAN® (naloxone HCl) Nasal Spray and future NARCAN sales; our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries; our ability to provide CDMO services for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines; the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations; our ability to negotiate new CDMO contracts and the negotiation of further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing CDMO contracts; our ability to collect reimbursement for raw materials and payment of services fees from our CDMO customers; the results of pending shareholder litigation and government investigations and their potential impact on our business; our ability to comply with the operating and financial covenants required by our senior secured credit facilities and the amended and restated credit agreement relating to such facilities, and our 3.875% Senior Unsecured Notes due 2028; our ability to refinance our senior secured credit facilities prior to their maturity in October 2023; the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to U.S. Food and Drug Administration marketing authorization, and corresponding procurement by government entities outside of the United States; the full impact of the COVID-19 pandemic on our markets, operations and employees as well as those of our customers and suppliers; the impact on our revenues from and duration of declines in sales of our vaccine products that target travelers due to the reduction of international travel caused by the COVID-19 pandemic; the ability of the Company and Bavarian Nordic to consummate the transactions contemplated under the agreement pursuant to which we agreed to sell our travel health business, to meet expectations regarding the conditions, timing and completion of the transactions, and to realize the potential benefits of the transactions; the impact of the organizational changes we announced in January 2023 on our business; our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria; the impact of cyber security incidents, including the risks from the interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties; the success of our commercialization, marketing and manufacturing capabilities and strategy; and the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. When evaluating our forward-looking statements, you should consider this cautionary statement along with the risks identified in our reports filed with the SEC. New factors emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

Trademarks

Emergent, BioThrax® (Anthrax Vaccine Adsorbed), RSDL® (Reactive Skin Decontamination Lotion Kit), BAT® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F and G)-(Equine)), Anthrasil® (Anthrax Immune Globulin Intravenous (Human)), VIGIV (Vaccinia Immune Globulin Intravenous (Human)), Trobigard® (atropine sulfate, obidoxime chloride), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), Vivotif® (Typhoid Vaccine Live Oral Ty21a), Vaxchora® (Cholera Vaccine, Live, Oral), NARCAN® (naloxone HCl) Nasal Spray, TEMBEXA® (brincidofovir) and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.

INTRODUCTION

Non-GAAP Financial Measures

This presentation contains financial measures (Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Shares, Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization), Adjusted Gross Margin, Adjusted Gross Margin %, Adjusted Revenues, and Adjusted Cost of Sales) that are considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. For its non-GAAP measures, the Company adjusts for specified items that can be highly variable or difficult to predict, or reflect the noncash impact of charges or accounting changes. As needed, such adjustments are tax effected utilizing the federal statutory tax rate for the U.S., except for changes in the fair value of contingent consideration as the vast majority is non-deductible for tax purposes. The Company views these non-GAAP financial measures as a means to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the Company’s business. For more information on these non-GAAP financial measures, please see the tables captioned “Reconciliation of Net Loss and Net Loss per Diluted Share to Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share,” “Reconciliation of Net Income Loss to Adjusted EBITDA,” and “Reconciliation of Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin %” included at the end of this presentation.

The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. For additional information on the non-GAAP financial measures noted here, please refer to the reconciliation tables provide in the Appendix to this presentation as well as the associated press release which can be found on the Company’s website at www.emergentbiosolutions.com.

INTRODUCTION

Agenda

1**Who We Are****2****What We Do****3****Our Products
Segment****4****Our CDMO
Services
Segment****5****Financial Status****6****Key
Takeaways**

Who We Are



About Us

For **nearly 25 years**, we've been at work defending people from things we hope will never happen—so we are prepared, just in case they ever do.

We provide **solutions** for complex and urgent **public health threats** through a **portfolio of vaccines and therapeutics** that we develop and manufacture for governments and consumers.

We also offer a range of **integrated contract development and manufacturing services** for pharmaceutical and biotechnology customers.

We do what we do because we want to create a better, more secure world—one where preparedness protects us from the threats we face.

Our mission is simple –
to protect and enhance life

THE COMPANY | WHO WE ARE

Our Vision

In furtherance of our mission, we set a goal to protect or enhance **one billion lives** by 2030.

PROTECT OR ENHANCE
ONE BILLION
LIVES
BY 2030



340M+
AS OF Q1 2023

What We Do




THE COMPANY | WHAT WE DO


Our Segments

1 PRODUCTS BUSINESS

GOVERNMENT/MCM¹



COMMERCIAL



CONTRACT DEVELOPMENT & MANUFACTURING (CDMO)

2 SERVICES BUSINESS

1. MCM = Medical Countermeasures

THE COMPANY | WHAT WE DO

Where We Are














Our Products Segment



Our Products

THREAT FOCUS	PRODUCTS			
ANTHRAX	Anthrasil [®] [Anthrax Immune Globulin Intravenous (human)]	AV7909 ¹ [Anthrax Vaccine Adsorbed (AVA), Adjuvanted]	BioThrax [®] [Anthrax Vaccine Adsorbed]	raxibacumab injection A fully human monoclonal antibody
SMALLPOX	ACAM2000 [®] [Smallpox (Vaccinia) Vaccine, Live]	VIGIV CNJ-016 [®] [Vaccinia Immune Globulin Intravenous (Human)]	TEMBEXA [®] [Brincidofovir]	
BOTULISM	BAT [®] [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)]			
EBOLA	EBANGA [™] [Ansuvimab--zykl]			
CHEMICAL THREATS	RSDL [®] [Reactive Skin Decontamination Lotion Kit]			
NERVE AGENT ANTIDOTES	Trobigard ^{®1} [atropine sulfate, obidoxime chloride auto-injector]			
OPIOID USE DISORDER	NARCAN [®] [naloxone HCl] Nasal Spray			

Our Science & Development (S&D) initiatives

PROGRAM	EXTERNAL PARTNER	CURRENT STATUS	PIPELINE TARGET
 AV7909 (Anthrax Vaccine Adsorbed (AVA), Adjuvanted)	BARDA	PHASE 3	INFECTIOUS DISEASE
 Ketamine (Analgesic ketamine)	USAMMDA	PHASE 3	PAIN MANAGEMENT
 UniFlu (Universal influenza vaccine)	NA	PHASE 1	INFECTIOUS DISEASE
 WEVEE VLP (Western, Eastern and Venezuelan equine encephalitic VLP vaccine)	NA	PHASE 1	INFECTIOUS DISEASE
 EBS-Lassa (rVSV-vectored vaccine for Lassa fever)	CEPI	PHASE 1	INFECTIOUS DISEASE
 EBS-Marburg (rVSV-vectored vaccine for Marburg virus disease)	NA	PRECLINICAL	INFECTIOUS DISEASE
 EBS-Sudan (rVSV-vectored vaccine for Sudan virus disease)	NA	PRECLINICAL	INFECTIOUS DISEASE
 Pan-Ebola mAb (Ebola/Sudan monoclonal)	IBT	PRECLINICAL	INFECTIOUS DISEASE
 CGRD-001 (Pralidoxime chloride/atropine auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
 EGRD-001 (Diazepam auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
 SIAN (Stabilized isoamyl nitrite)	BARDA/SwRI	PHASE 1	CHEMICAL AGENT ANTIDOTE



Vaccine
(injectable, oral)



THERAPEUTICS
(hyperimmune/mAb)



DRUG-DEVICE COMBINATIONS
(device, drug-device combination product)

- BARDA - Biomedical Advanced Research and Development Authority
- CEPI - Coalition for Epidemic Preparedness Innovations
- DoD - U.S. Department of Defense
- IBT - Integrated BioTherapeutics
- NIAID - National Institute of Allergy and Infectious Diseases
- SwRI - Southwest Research Institute
- USAMMDA - U.S. Army Medical Materiel Development Activity

Our CDMO Services Segment



CDMO Services Overview

Contract Development & Manufacturing (CDMO) offerings



Development services



Drug substance




Drug product & packaging

Sustainable competitive advantages

- Molecule-to-market services
- Flexible and scalable technologies
- Industry-leading track record
- Speed and flexibility to market

Technology Platforms



Mammalian



Plasma Protein



Viral

THE COMPANY | CDMO SERVICES SEGMENT

CDMO Core Development & Manufacturing Network



Gaithersburg



Bayview



Camden



Rockville



Winnipeg



Development Services



Drug Substance



Drug Product



Drug Product



Fully integrated Specialty CDMO

50+

EMPLOYEES

Mammalian
Viral
Next Gen
formulations

~300

EMPLOYEES

Mammalian

300+

EMPLOYEES

Vial
Lyo
Syringe

115+

EMPLOYEES

Vials

~300

EMPLOYEES

Plasma Proteins
mRNA Formulation
and Filling

- 48,000 sq. ft. flagship location centralizes development services, enabling scientific exchange across our CDMO network
- Formulation, process, and analytical development services

- Four segregated, flexible manufacturing suites – clinical & commercial scale
- 50-4000L single-use bioreactors

- 87,000 sq. ft. manufacturing focused on drug product manufacturing for non-viral therapeutics- clinical and commercial
- Isolator multi-format line: PFS and vials, integrated lyophilizer
- Packaging & labeling

- 70,000 sq. ft. facility focused on viral vaccine production
- 1 high speed isolator fill line with formulation suite, automated visual inspection, and automated labeling/ packaging line
- 1 filling suite dedicated to production of ACAM

- 150,000 sq. ft. facility comprised of three buildings for non-viral drug substance and drug product manufacturing
- Drug Substance manufacturing for plasma-derived products
- Isolator technology ideal for high value, small scale clinical or commercial biologics

Our CDMO Services Revenue – Since 2014 Launch

	Launch and Initial Ramp Up						COVID Response		Business Re-baselining	
[\$M]	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Forecast
CDMO Revenues	\$30.9	\$43.0	\$49.1	\$68.9	\$98.9	\$80.0	\$450.5	\$634.6	\$113.3	\$100.0 ¹
Total Period Revenues	\$404.5	\$489.3	\$488.8	\$560.9	\$782.4	\$1,106.0	\$1,555.4	\$1,792.7	\$1,120.9	\$1,150.0 ²
CDMO as % of Total Revenues	8%	9%	10%	12%	13%	7%	29%	35%	10%	11%

1. Reflects the midpoint of the range for CDMO revenues as indicated in the press release issued by the Company on May 9, 2023.

2. Reflects the midpoint of the range for Total revenues as indicated in the press release issued by the Company on May 9, 2023.

Financials

19



Overview of Q1 2023


1. Q1 2023 performance in-line with expectations
2. Revenues above our guidance range
3. Operating costs higher than expected
4. Period profitability negatively impacted
5. Remain committed to continuing to take actions aimed at strengthening our core business and building a foundation for sustainable, long-term growth
 - *Continued evidence of robust demand for NARCAN from both US PIP and Canadian channels; significant increase in NARCAN FY 2023 guidance*
 - *Important evidence of continued USG commitment to preparedness – recent issuances of ACAM, VIGIV and BAT notices of intent to procure*
 - *CDMO FY 2023 guidance adjusted down; unwinding of COVID work plus ongoing remediation costs and investments to improve, strengthen quality and compliance network wide*

FINANCIALS

Key Financial Performance Metrics Q1 2023 vs. Q1 2022¹

(\$ IN MILLIONS, EXCEPT PER SHARE AMOUNTS)

■ Q1 2022 ■ Q1 2023



1. All financial information incorporated within this presentation is unaudited.
2. See the Appendix for a definition of non-GAAP terms and reconciliation tables.

FINANCIALS

Notable Revenue Elements Q1 2023 vs. Q1 2022¹

(\$ IN MILLIONS, EXCEPT PER SHARE AMOUNTS)

(\$ in millions)	Q1 2023	Q1 2022	% Change
Product sales, net ⁽³⁾ :			
• Anthrax MCM	\$21.9	\$109.4	(80)%
• NARCAN	\$100.4	\$93.1	8%
• Smallpox MCM	\$7.2	\$23.3	(69)%
• Other Products	\$13.9	\$11.3	23%
Total product sales, net	\$143.4	\$237.1	(40)%
Contract development and manufacturing ("CDMO"):			
• Services	\$13.4	\$51.8	(74)%
• Leases	\$1.8	\$9.0	(80)%
Total CDMO	\$15.2	\$60.8	(75)%
Contracts and grants	\$6.5	\$9.6	(32)%
Total revenues	\$165.1	\$307.5	(46)%
<i>NM - Not Meaningful</i>			

1. All financial information incorporated within this presentation is unaudited.


3. Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with U.S. generally accepted accounting principles

FINANCIALS

Key Financial Performance Metrics Q1 2023 vs. Q1 2022

(\$ IN MILLIONS)

■ Q1 2022 ■ Q1 2023




1. R&D Margin is calculated as Gross R&D Expense divided by Total Revenues.
 2. SG&A Margin is calculated as Gross SG&A Expense divided by Total Revenues.
 3. See the Appendix for a definition of non-GAAP terms and reconciliation tables.

FINANCIALS

Segment Reporting Q1 2023 vs. Q1 2022¹

(\$ IN MILLIONS)

■ Q1 2022 ■ Q1 2023



1. For additional detail related to the method and specific inputs by which both revenue and adjusted gross margin are calculated, please refer to the table in the section entitled “Additional Financial Information” found in the press release issued by the Company on May 9, 2023.
 2. See the Appendix for a definition of non-GAAP terms and reconciliation tables.

FINANCIALS

Balance Sheet & Cash Flow Metrics

(\$ IN MILLIONS)

As of March 31, 2023

CASH **\$430.2**ACCOUNTS RECEIVABLE **\$155.9**NET DEBT POSITION^{1,2} **\$975.0**

For the Three Months Ended March 31, 2023

OPERATING CASH FLOW **\$(184.0)**CAPITAL EXPENDITURES **\$15.1**

2023 Forecast – Updated as of 05/09/2023

Full Year 2023

METRIC (\$ in millions)	Updated Range (as of 05/09/23)	Action	Previous Range (as of 02/27/23)
Total Revenues	\$1,100 - \$1,200	UNCHANGED	\$1,100 - \$1,200
Net Loss	\$(185) - \$(135)	REVISED	\$(180) - \$(130)
Adjusted Net Loss ⁽²⁾	\$(85) - \$(35)	REVISED	\$(80) - \$(30)
Adjusted EBITDA ⁽²⁾	\$100 - \$150	REVISED	\$75 - \$125
Adjusted Gross Margin % ⁽²⁾	39% - 42%	REVISED	41% - 44%
Product/Service Level Revenue			
• Anthrax MCM	\$260 - \$280	UNCHANGED	\$260 - \$280
• NARCAN	\$360 - \$380	REVISED	\$290 - \$310
• Smallpox MCM	\$235 - \$255	UNCHANGED	\$235 - \$255
• Other Products	\$120 - \$140	REVISED	\$165 - \$185
• CDMO	\$90 - \$110	REVISED	\$115 - \$135

Q2 2023

(\$ in millions)	Q2 2023 Forecast
Total Revenues	\$210 - \$230


2. See the Appendix for a definition of non-GAAP terms and reconciliation tables.

FINANCIALS

Historical Revenues – 2017-2023F

(\$ IN MILLIONS)

■ PRODUCTS ■ CDMO ■ C&G



1. Reflects the midpoints of the ranges for each category indicated in a press release issued by the Company on May 9, 2023.

Key Takeaways



Current Status of 2023 Priorities

- ✓ Sale of Travel Health business to Bavarian Nordic; \$270M upfront + up to \$110M in sales and development-based milestones
 - ✓ NARCAN Nasal Spray approved by FDA as first and only opioid overdose reversal treatment available over the counter; remain focused on expanding access and maintaining affordability; targeting late summer launch
 - ✓ Amendment and extension of existing syndicated credit agreement – maturity date extended to May 15, 2025; reduced revolver size to \$300M; reduced senior secured indebtedness by +50%; established \$150M ATM (minimum \$75M raise by April 30, 2024)
1. Continue to support longstanding partnership with the US government focused on preparedness and response against public health threats – i) three notices of intent to procure from USG for **ACAM2000**, VIGIV and BAT; ii) AV7909 BLA tracking to July 2023 PDUFA
 2. Continue to implement strategy of delivering and strengthening our quality and compliance culture and systems
 3. Actively managing our business and capital structure

KEY TAKEAWAYS

State of the NARCAN Franchise

- FDA approval of NARCAN OTC (3/29/23) – opportunity to expand availability through pharmacies, convenience stores, vending machines, online retailers...anywhere OTC products are found
- Meeting with retail partners, finalizing contracts and distribution plans; continuing to support and advocate for potential insurance coverage for Medicare/Medicaid patients
- Confident we have sufficient supply chain capacity to fulfill demand; goal of late summer for OTC product available
- Committed to working with public interest partners, as they are and will continue to be a critical point of access for NARCAN
- Continue to seek markets outside US, namely Canada
- Further evaluating making NARCAN as widely accessible as possible

4mg Doses
Distributed
in US/Canada
(since 02/2016)

+44M

Target retail price for
carton of two 4mg.
doses

<\$50
(<\$25/dose)

Important Deliverables

- ACAM2000 contract mod and resumption of product deliveries to SNS
- AV7909 July PDUFA; contours of potential future SNS procurement contract
- NARCAN Nasal Spray OTC launch
- CDMO business incremental (quarter-to-quarter) operational improvement
- Q2/YTD 2023 results – anticipated early August

Q&A



Appendix

2023 Forecast – Key Assumptions

- **OVERALL** — Reflects the impact of the previously announced sale of the Travel Health business to Bavarian Nordic, which is anticipated to close in the second quarter.
- **Total Revenues** — Unchanged, reflecting the neutral impact of the overall updates across all sources of revenues.
- **Anthrax MCM** — Unchanged, reflecting assumptions that have remained constant regarding procurement and delivery of the Company's related products to the U.S. and allied governments.
- **NARCAN** — Revised, primarily reflecting robust demand from the U.S. PIP (public interest) channel and Canadian market.
- **Smallpox MCM** — Unchanged, reflecting assumptions that have remained constant regarding procurement and delivery of the Company's related products to the U.S. and allied governments.
- **Other Products** — Revised, reflecting the removal of the Travel Health products, Vaxchora and Vivotif, following the anticipated completion of the divestiture of this business.
- **CDMO** — Revised, reflecting the impact of recent changes to customer requirements for COVID-related products coupled with continued remediation costs and investments to improve quality and compliance across the Company's manufacturing network.
- **Adjusted Net Loss** — Revised, reflecting the impact of higher NARCAN sales and the Travel Health business divestiture, offset by lower CDMO revenues and an increase in the tax valuation allowance.
- **Adjusted EBITDA** — Revised, reflecting the impact of higher NARCAN sales and the Travel Health business divestiture, offset by lower CDMO revenues.
- **Adjusted Gross Margin** — Revised, reflecting the impact of overall revenue mix.

Revenues and profits in 2023 are expected to be weighted towards the second half of the year

APPENDIX

Reconciliation of Net Loss and Net Loss per Diluted Share to Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share – Q1 2023 vs. Q1 2022

(\$ in millions, except per share value)	Three Months Ended March 31.		
	2023	2022	Source
Net loss	\$(183.0)	\$(3.7)	
Adjustments:			
Non-cash amortization charges	18.0	15.1	Intangible Asset (IA) Amortization, Other Income
Changes in fair value of contingent consideration	1.5	0.5	Product COGS
Restructuring costs	9.7	—	Restructuring expense
Divestiture related costs	1.0	—	
Acquisition-related costs (transaction & integration)	0.1	0.4	SG&A
Tax effect	(6.1)	(3.2)	
Total adjustments:	\$24.2	\$12.8	
Adjusted net income (loss)	\$(158.8)	\$9.1	
Net loss per diluted share	\$(3.65)	\$(0.07)	
Adjustments:			
Non-cash amortization charges	0.36	0.29	IA)Amortization, Other Income
Changes in fair value of contingent consideration	0.03	0.01	Product COGS
Restructuring costs	0.19	—	Restructuring expense
Divestiture related costs	0.02	—	
Acquisition-related costs (transaction & integration)	—	0.01	SG&A
Tax effect	(0.12)	(0.06)	
Total adjustments:	\$0.48	\$0.25	
Adjusted net income (loss) per diluted share	\$(3.17)	\$0.18	
Diluted shares used in computing adjusted net income (loss) per diluted share	50.2	50.7	

APPENDIX

Reconciliation of Net Loss to Adjusted Net Loss – FY 2023 Forecast

(\$ in millions)	2023 Revised Full Year Forecast	Source
Net loss	\$(185) - \$(135)	
Adjustments:		
Non-cash amortization charges	\$70	IA Amortization
Changes in fair value of contingent consideration	\$3	Product COGS
Restructuring costs	\$10	Restructuring expense
Acquisition-related costs (transaction & integration)	\$32	SG&A
Inventory Step-up provision	\$6	Product COGS
Divestiture related costs	\$6	SG&A
Tax effect	(\$27)	
Total adjustments:	\$100	
Adjusted net loss	\$(85) - \$(35)	

APPENDIX

Reconciliation of Net Loss to Adjusted EBITDA – Q1 2023 vs. Q1 2022

(\$ in millions)	Three Months Ended March 31,	
	2023	2022
Net loss	\$(183.0)	\$(3.7)
Adjustments:		
Depreciation & amortization	34.6	30.9
Income taxes	21.9	(0.1)
Total interest expense, net	13.4	8.0
Changes in fair value of contingent consideration	1.5	0.5
Restructuring costs	9.7	—
Divestiture related costs	1.0	—
Acquisition-related costs (transaction & integration)	0.1	0.4
Total adjustments	\$82.2	\$39.7
Adjusted EBITDA	\$(100.8)	\$36.0

APPENDIX

Reconciliation of Net Loss to Adjusted EBITDA – FY 2023 Forecast

(\$ in millions)	2023 Revised Full Year Forecast
Net loss	\$(185) - \$(135)
Adjustments:	
Depreciation & amortization	\$140
Income Taxes	18
Total interest expense, net	70
Changes in fair value of contingent consideration	3
Restructuring costs	10
Acquisition-related costs (transaction & integration)	32
Inventory Step-up provision	6
Divestiture related costs	6
Total adjustments	\$285
Adjusted EBITDA	\$100 - \$150

APPENDIX

Reconciliation of Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin % – Q1 2023 vs. Q1 2022

(\$ in millions)	Three Months Ended March 31,	
	2023	2022
Total revenues	\$165.1	\$307.5
Contract and grants revenues	\$(6.5)	\$(9.6)
Adjusted revenues	\$158.6	\$297.9
Cost of product sales	\$102.9	\$80.3
Cost of contract development and manufacturing	\$52.2	\$75.6
Cost of product sales and cost of contract development and manufacturing services ("COGS")	\$155.1	\$155.9
Changes in fair value of contingent consideration	\$(1.5)	\$(0.5)
Restructuring costs	\$(2.0)	\$—
Adjusted COGS	\$151.6	\$155.4
Gross margin (adjusted revenues minus COGS)	\$3.5	\$142.0
Gross margin % (gross margin divided by adjusted revenues)	2%	48%
Adjusted gross margin (adjusted revenues minus adjusted COGS)	\$7.0	\$142.5
Adjusted gross margin % (adjusted gross margin divided by adjusted revenues)	4%	48%

APPENDIX

Reconciliation of Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin % – FY 2023 Forecast

(\$ in millions)	2023 Revised Full Year Forecast
Total Revenues	\$1,100 - \$1,200
Contracts and Grants Revenues	\$(35)
Adjusted Revenues	\$1,065 - \$1,165
COGS	\$660 - \$682
Changes in fair value of contingent consideration and Other Items	(\$10)
Adjusted COGS	\$650 - \$672
Gross margin (adjusted revenues minus COGS)	\$405 - \$483
Gross margin % (gross margin divided by adjusted revenues)	38% - 41%
Adjusted gross margin (adjusted revenues minus adjusted COGS)	\$415 - \$493
Adjusted gross margin % (adjusted gross margin divided by adjusted revenues)	39% - 42%

APPENDIX

Reconciliation of Segment Level (Products and Services) Total Revenues to Adjusted Revenues, Cost of Sales to Adjusted Cost of Sales, and Gross Margin and Gross Margin % to Adjusted Gross Margin and Adjusted Gross Margin % – Q1 2023 vs. Q1 2022

(\$ in millions)	Products			Services		
	Three Months Ended March 31,			Three Months Ended March 31,		
	2023	2022	% Change	2023	2022	% Change
Revenues	\$143.4	\$237.1	(40)%	\$15.2	\$60.8	(75)%
Cost of sales	\$102.9	\$80.3	28%	\$52.2	\$75.6	(31)%
Less: Changes in fair value of contingent consideration	\$1.5	\$0.5	*	\$—	\$—	NM
Less: Restructuring costs	\$2.0	\$—	NM	\$—	\$—	NM
Adjusted cost of sales **	\$99.4	\$79.8	25%	\$52.2	\$75.6	(31)%
Gross margin ***	\$40.5	\$156.8	(74)%	\$(37.0)	\$(14.8)	*
Gross margin % ***	28%	66%	NM	(243)%	(24)%	NM
Adjusted gross margin ****	\$44.0	\$157.3	(72)%	\$(37.0)	\$(14.8)	*
Adjusted gross margin % ****	31%	66%	NM	(243)%	(24)%	NM
* % change is greater than +/- 100%						
** Adjusted cost of sales, which is a non-GAAP financial measure, is calculated as cost of sales less restructuring costs, and other special items and non-cash items related to changes in fair value of contingent consideration. See "Reconciliation of Non-GAAP Measures" for the reconciliation of this non-GAAP measure to the most closely related GAAP financial measure.						
*** Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues.						
**** Adjusted gross margin, which is a non-GAAP financial measure, is calculated as revenues less Adjusted cost of sales. Adjusted gross margin %, which is a non-GAAP financial measure, is calculated as Adjusted gross margin divided by revenues. See "Reconciliation of Non-GAAP Measures" for the reconciliation of this non-GAAP measure to the most closely related GAAP financial measure.						
NM - Not Meaningful						

EMERGENT[®]

www.emergentbiosolutions.com